Remove 2003 Remove Competition Remove Pharmaceutical manufacturing
article thumbnail

Building CO2-neutral, defossilised supply chains for chemicals

European Pharmaceutical Review

2 However, most of these efforts relating to catalysis, 3 process waste metrics, 4 lifecycle assessments, 5 pharmaceuticals in the environment 6 and the phase out of substances of concern 7 mainly mitigate the consequences of pharmaceutical manufacturing. Defossilization of pharmaceutical manufacturing.

article thumbnail

Biosimilars Market Set for Biggest Year Yet in 2023

PM360

Although AbbVie’s patent for Humira officially expired in 2016, the legal and regulatory delays paused competition for Humira until 2023. pharmaceutical industry. Financial incentives were explored further in the survey as biosimilars are expected to increase competition, thereby lower cost and increase access.